Edwards Lifesciences (EW) Share-based Compensation (2009 - 2026)

Edwards Lifesciences' Share-based Compensation history runs 18 years deep, the most recent figure standing at $45.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 12.94% year-over-year to $45.4 million in Q1 2026; TTM through Mar 2026 was $163.3 million, a 3.42% increase from a year earlier, with the FY2025 full-year figure at $158.1 million, down 2.59% from the prior year.
• Share-based Compensation improved to $45.4 million in Q1 2026 per EW's latest filing, from $39.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $45.4 million in Q1 2026 and bottomed at $27.9 million in Q4 2022.
• The 5-year median for Share-based Compensation is $37.5 million (2025), against an average of $37.2 million.
• Across the five-year window, Share-based Compensation increased 29.14% in 2024 and fell 14.58% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $27.9 million in 2022, then climbed by 9.32% to $30.5 million in 2023, then climbed by 3.93% to $31.7 million in 2024, then increased by 23.66% to $39.2 million in 2025, then rose by 15.82% to $45.4 million in 2026.
• Per Business Quant, the three latest EW Share-based Compensation figures stand at $45.4 million (Q1 2026), $39.2 million (Q4 2025), and $41.2 million (Q3 2025).